Rydapt

Astellas’ Xospata wins AML approval, with Daiichi close behind

Astellas will likely soon be joined by Daiichi in relapsed/refractory FLT3-mutated AML, and both have eyes on Novartis' Rydapt.

Angus Liu Nov 29, 2018 10:31am

NICE issues early 'no' on RoActemra, Rydapt

Dec 6, 2017 12:00pm

Novartis wins FDA nod for Rydapt, new targeted drug for AML

Apr 28, 2017 11:36am